WallStSmart

AbbVie Inc (ABBV)vsCrowdstrike Holdings Inc (CRWD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 1171% more annual revenue ($61.16B vs $4.81B). ABBV leads profitability with a 6.9% profit margin vs -3.4%. ABBV appears more attractively valued with a PEG of 0.49. ABBV earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.39

CRWD

Hold

40

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 4.0Quality: 4.3
Piotroski: 1/9Altman Z: 1.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-1190.8%)

Margin of Safety

-1190.8%

Fair Value

$16.05

Current Price

$207.18

$191.13 premium

UndervaluedFair: $16.05Overvalued

Intrinsic value data unavailable for CRWD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$362.83B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4910/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

CRWD2 strengths · Avg: 8.5/10
Market CapQuality
$99.67B9/10

Large-cap with strong market position

Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
87.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.392/10

Distress zone — elevated risk

CRWD4 concerns · Avg: 2.5/10
Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
3.372/10

Expensive relative to growth rate

Price/BookValuation
22.1x2/10

Trading at 22.1x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : CRWD

The strongest argument for CRWD centers on Market Cap, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 87.0x leaves little room for execution misses.

Bear Case : CRWD

The primary concerns for CRWD are Operating Margin, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

ABBV profiles as a value stock while CRWD is a growth play — different risk/reward profiles.

CRWD carries more volatility with a beta of 1.12 — expect wider price swings.

CRWD is growing revenue faster at 23.3% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (63/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Crowdstrike Holdings Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

CrowdStrike Holdings, Inc. provides cloud solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. The company is headquartered in Sunnyvale, California.

Want to dig deeper into these stocks?